Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Pemetrexed
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2018-09-10

Last Posted Date: 2024-08-22

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 118

Registration Number: NCT03664024

Locations: 🇨🇦
CISSS de la Monteregie-Centre ( Site 0801), Greenfield Park, Quebec, Canada
🇭🇺
Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0401), Szolnok, Hungary
🇮🇱
Meir Medical Center ( Site 0501), Kfar-Saba, Israel

and more 12 locations

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Tislelizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2018-09-10

Last Posted Date: 2024-11-25

Lead Sponsor: BeiGene

Target Recruit Count: 334

Registration Number: NCT03663205

Locations: 🇨🇳
Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳
Yunnan Cancer Hospital, Kunming, Yunnan, China

and more 44 locations

Dose Individualization of Pemetrexed - IMPROVE-II

Phase 4

Terminated

Conditions: Non Small Cell Lung Cancer
Mesothelioma

Interventions: Drug: Pemetrexed

First Posted Date: 2018-08-31

Last Posted Date: 2022-05-13

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 81

Registration Number: NCT03655821

Locations: 🇳🇱
Maastricht University Medical centre, Maastricht, Netherlands
🇳🇱
Radboud university medical centre, Nijmegen, Netherlands
🇳🇱
Erasmus University Medical Centre, Rotterdam, Netherlands

and more 2 locations

Dose Individualization of Pemetrexed - IMPROVE-III

Phase 4

Completed

Conditions: Non Small Cell Lung Cancer
Mesothelioma

Interventions: Drug: Pemetrexed

First Posted Date: 2018-08-31

Last Posted Date: 2022-05-10

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 10

Registration Number: NCT03655834

Locations: 🇳🇱
Antoni van Leeuwenhoek, Amsterdam, Netherlands
🇳🇱
Maastricht University Medical centre, Maastricht, Netherlands
🇳🇱
Radboud university medical centre, Nijmegen, Netherlands

and more 2 locations

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Phase 2

Conditions: EGFR Activating Mutation
NSCLC Stage IV
NSCLC Stage IIIB

Interventions: Drug: Atezolizumab
Drug: Bevacizumab
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2018-08-27

Last Posted Date: 2019-04-17

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 40

Registration Number: NCT03647956

Locations: 🇭🇰
Department of Clinical Oncology, Hong Kong, Hong Kong

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

Phase 3

Active, not recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: canakinumab
Drug: canakinumab-matching placebo
Drug: pembrolizumab
Drug: carboplatin
Drug: cisplatin
Drug: pemetrexed
Drug: paclitaxel
Drug: nab-paclitaxel

First Posted Date: 2018-08-15

Last Posted Date: 2024-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 673

Registration Number: NCT03631199

Locations: 🇺🇸
Pacific Shores Medical Group ., Long Beach, California, United States
🇺🇸
USC Kenneth Norris Comprehensive Cancer Center ., Los Angeles, California, United States
🇺🇸
Advent Health Cancer Institute, Orlando, Florida, United States

and more 2 locations

Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

Phase 1

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Pembrolizumab
Drug: Pemetrexed
Drug: Dexamethasone
Drug: Oxaliplatin
Dietary Supplement: Folic Acid
Dietary Supplement: Vitamin B-12

First Posted Date: 2018-08-13

Last Posted Date: 2022-06-10

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 33

Registration Number: NCT03626922

Locations: 🇺🇸
Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States
🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸
Minnesota Oncology-Minneapolis, Minneapolis, Minnesota, United States

and more 12 locations

Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC.

Phase 2

Withdrawn

Conditions: Efficacy and Safety

Interventions: Drug: JS001
Drug: Pemetrexed
Procedure: Thoracic Surgery
Drug: Carboplatin

First Posted Date: 2018-08-09

Last Posted Date: 2024-12-06

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 80

Registration Number: NCT03623776

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Phase 3

Completed

Conditions: Lung Neoplasms

Interventions: Drug: Sintilimab
Drug: Pemetrexed
Drug: Platinum
Drug: Placebos

First Posted Date: 2018-07-31

Last Posted Date: 2023-02-27

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 397

Registration Number: NCT03607539

Locations: 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, China

Pemetrexed in Maintenance in Patients With Impaired Renal Function, 2 Dose Calculation Strategies

Phase 4

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pemetrexed

First Posted Date: 2018-07-31

Last Posted Date: 2021-05-24

Lead Sponsor: Centre Georges Francois Leclerc

Target Recruit Count: 11

Registration Number: NCT03607149

Locations: 🇫🇷
Centre Georges Francois Leclerc, Dijon, France
🇫🇷
CH William Morey, Chalon-sur-Saône, France
🇫🇷
Centre Universitaire Hospitalier de Dijon, Dijon, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy